Vaxart, Inc. (VXRT): Nasdaq/NYSE listing notice — Vaxart receives second 180-day Nasdaq extension to cure bid price deficiency until June 30, 2025

Vaxart, Inc.

Nasdaq notified Vaxart on Dec 31, 2024 of an additional 180-day compliance period to meet the $1.00 minimum bid price requirement.
Extension moves the cure deadline from Dec 30, 2024 to June 30, 2025.
Company is considering a reverse stock split as a potential cure for the deficiency.
If not compliant by June 30, 2025, Nasdaq will issue a delisting notice; Vaxart may appeal.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until December 30, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until June 30, 2025

View on SEC.gov

Browse all listing & compliance notices →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-038599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.